1263188-14-2Relevant academic research and scientific papers
7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis
Thompson, Andrew M.,O’Connor, Patrick D.,Marshall, Andrew J.,Yardley, Vanessa,Maes, Louis,Gupta, Suman,Launay, Delphine,Braillard, Stephanie,Chatelain, Eric,Franzblau, Scott G.,Wan, Baojie,Wang, Yuehong,Ma, Zhenkun,Cooper, Christopher B.,Denny, William A.
supporting information, p. 4212 - 4233 (2017/06/05)
Within a backup program for the clinical investigational agent pretomanid (PA-824), scaffold hopping from delamanid inspired the discovery of a novel class of potent antitubercular agents that unexpectedly possessed notable utility against the kinetoplast
NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES
-
Page/Page column 17, (2011/02/25)
The current invention pertains to nitroimidazooxazine and nitroimidazooxazole analogues, their methods of preparation, and uses of the compounds as treatment for Mycobacterium tuberculosis, for use as anti-tubercular drugs, for use as anti-protozoal agents with unexpectedly high potency against Trypanosoma cruzi or Leishmania donovani, and for the treatment of other microbial infections.
